What the research found
Researchers conducted a comprehensive review of trials testing obesity medications started in adults over a one-year period. They compiled data from 180 reports covering nearly 81,000 participants, though only 50 trial arms provided adequate data for the main analysis. Using statistical modelling, they ranked medications by weight loss: retatrutide 12 mg showed the largest placebo-adjusted reduction, followed by tirzepatide 15 mg and cagrilintide-semaglutide 2.4/2.4 mg.
However, the evidence base has significant gaps. Only two drugs—tirzepatide 15 mg and semaglutide 2.4 mg—met high-certainty standards. The authors found very limited randomised data comparing different titration schedules or testing whether added lifestyle interventions improve outcomes. Notably, weight loss in people with type 2 diabetes was substantially less (about 62% of the effect seen in non-diabetic participants), suggesting treatment response varies by metabolic status.
Why it matters for you
If you're considering starting a GLP-1 or dual/triple receptor agonist, this research confirms the drugs work but highlights what isn't well studied. Most trials stop at or before 12 months—real-world protocols often involve dose escalation over weeks or months, yet head-to-head comparisons of titration schedules barely exist in the published literature. This means your clinician's choice of starting dose and titration pace is likely informed more by experience than by randomised evidence.
The finding that metabolic status affects response (smaller losses in diabetics) is relevant if you track fasting glucose, HbA1c, or HOMA-IR. It suggests you shouldn't expect the same magnitude of weight reduction advertised in trials if your baseline metabolic health is compromised. Finally, the lack of rigorous lifestyle-support trials is telling: most drug trials bundle pharmacotherapy with dietary or exercise counselling, making it hard to isolate how much of the benefit comes from behaviour change versus the compound itself—important context when evaluating your own results.
Caveats
- Only 50 of 180 trial arms had sufficient 1-year data; most evidence comes from shorter windows extrapolated forward
- Many dose–response comparisons are missing; only 5 of 22 adjacent dose increments were directly tested
- Weight loss in people with diabetes was 62% lower, but the reason isn't fully explained and may reflect different trial designs, not just pharmacology
- Most trials combined drug therapy with lifestyle advice, confounding the isolated effect of medication
- Publication bias likely favours positive trials; unpublished or null results are underrepresented